In the BioHarmony Drug Report Database
Ibrexafungerp
Brexafemme (ibrexafungerp) is a small molecule pharmaceutical. Ibrexafungerp was first approved as Brexafemme on 2021-06-01. It is used to treat vulvovaginal candidiasis in the USA. Brexafemme’s patents are valid until 2035-01-19 (FDA).
Trade Name
|
Brexafemme |
|---|---|
Common Name
|
ibrexafungerp |
ChEMBL ID
|
CHEMBL4297513 |
Indication
|
vulvovaginal candidiasis |
Drug Class
|
Antifungal |
Image (chem structure or protein)